Myriad's Shares Pop on Revised CMS Reimbursement Rates for BRCA1/2 Testing | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics' shares were up as much as 15 percent in Wednesday trading after the company said that the US Centers for Medicare and Medicaid Services had increased the reimbursement rate for the sequencing of BRCA1 and BRCA2 genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.